

# Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018

SAN DIEGO, March 8, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its fourth quarter and full year 2017 financial results will be released on Thursday, March 15, 2018, after the market close. Pfenex management will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the financial results and provide a business update.

Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call. A replay of the conference call will be available approximately one hour after the call until March 22, 2018. To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10117964. The conference call will also be available as a webcast. To access the webcast link please log on to [www.pfenex.com](http://www.pfenex.com) (<http://www.pfenex.com>).

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (<http://www.pfenex.com>), our investor relations website (<http://pfenex.investorroom.com>), press releases, SEC filings, public conference calls, corporate Twitter account (<https://twitter.com/pfenex>), Facebook page (<https://www.facebook.com/Pfenex-Inc-105908276167776/timeline>), and LinkedIn page (<https://www.linkedin.com/company/pfenex-inc>) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

## About Pfenex Inc.

Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology<sup>®</sup> to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo<sup>®</sup> (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis<sup>®</sup> and Neulasta<sup>®</sup>.

SOURCE Pfenex Inc.

For further information: For further information: Susan A. Knudson, Chief Financial Officer, (858) 352-4324, [sknudson@pfenex.com](mailto:sknudson@pfenex.com)

---